The impact of Ipilimumab (Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4)-antagonist), Nivolumab and Pembrolizumab (Programmed cell Death protein 1(PD-1)-antagonists), and Atezolizumab (Programmed Death-Ligand 1(PD-L1)-antagonist) on overall survival in cancer patients is relevant. Here, PDCD1 is linked to cancer.